Atopic Dermatitis Clinical Trials in Miami, Florida
11 recruitingMiami, Florida
Showing 1–11 of 11 trials
Recruiting
Phase 2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Atopic Dermatitis
UCB Biopharma SRL160 enrolled50 locationsNCT07277660
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 4
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Atopic Dermatitis
Eli Lilly and Company200 enrolled66 locationsNCT07006792
Recruiting
Phase 3
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Healthy ParticipantsAtopic Dermatitis
Pfizer119 enrolled3 locationsNCT06564389
Recruiting
Phase 2
A Study Evaluating TRIV-509 in Atopic Dermatitis
Atopic Dermatitis
Triveni Bio90 enrolled44 locationsNCT07167758
Recruiting
Phase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
LEO Pharma195 enrolled72 locationsNCT06311682
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Atopic Dermatitis
Galderma R&D1,000 enrolled108 locationsNCT06988605
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled97 locationsNCT05995964
Recruiting
Phase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Novartis Pharmaceuticals224 enrolled99 locationsNCT06947993
Recruiting
Phase 2
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Atopic Dermatitis (AD)
CAGE Bio Inc.180 enrolled16 locationsNCT06810050